Janus Henderson Group PLC Buys 99,517 Shares of CG Oncology, Inc. (NASDAQ:CGON)

Janus Henderson Group PLC lifted its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 7.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,526,534 shares of the company's stock after purchasing an additional 99,517 shares during the quarter. Janus Henderson Group PLC owned 2.28% of CG Oncology worth $57,596,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of CGON. California State Teachers Retirement System purchased a new stake in CG Oncology during the 1st quarter valued at about $103,000. Bank of New York Mellon Corp boosted its holdings in CG Oncology by 38.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 89,344 shares of the company's stock valued at $2,821,000 after acquiring an additional 24,801 shares during the period. Rhumbline Advisers boosted its holdings in CG Oncology by 13.0% during the 2nd quarter. Rhumbline Advisers now owns 34,229 shares of the company's stock valued at $1,081,000 after acquiring an additional 3,940 shares during the period. TD Asset Management Inc purchased a new stake in CG Oncology during the 2nd quarter valued at about $2,939,000. Finally, Massachusetts Financial Services Co. MA boosted its holdings in CG Oncology by 2.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 266,787 shares of the company's stock valued at $8,422,000 after acquiring an additional 6,899 shares during the period. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

CG Oncology Stock Up 3.1 %

Shares of NASDAQ:CGON traded up $1.03 during trading on Friday, hitting $34.59. The stock had a trading volume of 661,823 shares, compared to its average volume of 646,036. CG Oncology, Inc. has a 12 month low of $25.77 and a 12 month high of $50.23. The firm's fifty day moving average is $35.84 and its 200 day moving average is $34.84.

CG Oncology (NASDAQ:CGON - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.30 million. As a group, equities research analysts anticipate that CG Oncology, Inc. will post -1.31 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on CGON. Bank of America restated a "buy" rating and set a $65.00 target price on shares of CG Oncology in a report on Tuesday, October 8th. HC Wainwright reiterated a "buy" rating and issued a $75.00 price objective on shares of CG Oncology in a report on Friday. Roth Mkm assumed coverage on CG Oncology in a report on Tuesday, August 27th. They issued a "buy" rating and a $65.00 price objective for the company. Roth Capital upgraded CG Oncology to a "strong-buy" rating in a report on Tuesday, August 27th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $66.00 price objective on shares of CG Oncology in a report on Friday. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $63.88.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.